Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Zetia/Zocor Combo User Fee In July 2004; Genentech Sees Avastin On Time

This article was originally published in Pharmaceutical Approvals Monthly

  • News
  • Pharmaceutical Approvals Monthly

Executive Summary

The user fee deadline for Merck/Schering-Plough’s Zetia/Zocor combination product for cholesterol reduction is July 24, 2004.

You may also be interested in...



Schering Ends Sarasar Lung Cancer Trial, Leaving One Novel Agent In Phase III

Schering-Plough is discontinuing its Sarasar Phase III program in non-small cell lung cancer after an interim analysis suggested the data will not demonstrate efficacy.

Schering Ends Sarasar Lung Cancer Trial, Leaving One Novel Agent In Phase III

Schering-Plough is discontinuing its Sarasar Phase III program in non-small cell lung cancer after an interim analysis suggested the data will not demonstrate efficacy.

Abbott Files First Humira sBLA, AstraZeneca Seeks IV Nexium; More Filings

Abbott has kicked off its planned label expansion program for Humira with an Oct. 1 filing for an improved physical function claim in rheumatoid arthritis.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS002437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By